OTA inhibits expression of glutamate transporter 1 (GLT1), glutamate aspartate transporter (GLAST), that leads to reducing glutamate absorption by astrocytes, which play a potential role in stability or induction of neurodegenerative diseases like Parkinson’s and Alzheimer’s, as well as neuron motor degenerations [87,88]. Here, SLC1A2 is linked to Parkinson disease.